title: Absence of germline and somatic p53 alterations in children with sporadic brain tumors.
abstract: Cancers of the central nervous system are the most common solid tumors of childhood. Although somatic alterations of the p53 tumor suppressor gene have been implicated in brain tumorigenesis, the role of germline p53 mutations in the development of childhood brain tumors has not been well defined. As a component of an ongoing extensive study of the epidemiology of childhood brain tumors, we prospectively examined the germline and tumor p53 gene status in 85 children without a family history of cancer who were diagnosed with a sporadic malignant central nervous system tumor. Using PCR/single-strand conformational polymorphism analysis and direct DNA sequencing, 85 children were screened for the presence of constitutional p53 sequence alterations in exons 2 and 4 through 11. No mutations were identified. Commonly reported sequence polymorphisms were observed at codon 72, as well as in 2 other previously described nucleotide residues. Forty-four brain tumor samples were available for analysis and of these 40 were paired with peripheral blood. Once again, no p53 mutations were found. Of the 5 germline samples with the 2 common polymorphisms, only one had a paired tumor sample for comparison and the tumor contained the same alteration as the germline. Of note, one tumor, a PNET of the cerebellum (medulloblastoma), showed loss of heterozygosity at codon 72. We can conclude that the frequency of germline and somatic p53 mutations in sporadic childhood brain tumors is very low, probably less than 1%, and there is no need to screen these patients routinely for their germline p53 status. However, the potential significance of LOH at codon 72 remains to be elucidated.
authors.affiliation: Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Ontario, Canada.
authors.forename: C
authors.initials: C
authors.lastname: Portwine
authors.forename: S
authors.initials: S
authors.lastname: Chilton-MacNeill
authors.forename: C
authors.initials: C
authors.lastname: Brown
authors.forename: E
authors.initials: E
authors.lastname: Sexsmith
authors.forename: J
authors.initials: J
authors.lastname: McLaughlin
authors.forename: D
authors.initials: D
authors.lastname: Malkin
mesh_terms: D001932:Brain Neoplasms / Q000097:blood / Q000453:epidemiology / Q000235:genetics*; D002528:Cerebellar Neoplasms / Q000097:blood / Q000235:genetics; D002648:Child; D002675:Child, Preschool; D003062:Codon / Q000235:genetics; D004247:DNA / Q000097:blood / Q000235:genetics; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000235:genetics; D018303:Ganglioglioma / Q000097:blood / Q000453:epidemiology / Q000235:genetics; D016158:Genes, p53; D005838:Genotype; D018095:Germ-Line Mutation; D005910:Glioma / Q000097:blood / Q000453:epidemiology / Q000235:genetics; D006801:Humans; D007223:Infant; D019656:Loss of Heterozygosity; D008527:Medulloblastoma / Q000097:blood / Q000235:genetics; D018242:Neuroectodermal Tumors, Primitive / Q000097:blood / Q000453:epidemiology / Q000235:genetics; D016133:Polymerase Chain Reaction; D018807:Polymorphism, Single-Stranded Conformational; D011446:Prospective Studies
chemical_list: D003062:Codon; D004273:DNA, Neoplasm; D004247:DNA